Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 419

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 15
Chunk 419
---
 OPERATING EXPENSES      (4,935,696)  (4,409,122)             LOSS FROM OPERATIONS      (1,573,702)  (2,593,588)             FINANCE COSTS      (21,146)  (13,929)             LOSS BEFORE TAX      (1,594,848)  (2,607,517)             Tax expense:            Deferred tax      12,305   17,359 Income tax      (15,799)  (38,885)Tax expense      (3,494)  (21,526)             NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS      $(1,598,342) $(2,629,043)             Other comprehensive income/(loss):            Foreign currency translation gain/(loss)      122,294   (268,232)             COMPREHENSIVE LOSS     $(1,476,048) $(2,897,275)             Earnings per share - Basic and diluted      (0.090)  (0.166)Weighted average number of common stocks outstanding, Basic and Diluted       17,818,483  15,875,455 

# Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 12.

See accompanying notes to the consolidated financial statements.

 F-6Table of Contents

BIONEXUS GENE LAB CORP

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY 

FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023 

(Currency expressed in United States Dollars (“US$”)) 

(Audited)

  Common stock            Number     Additional  Accumulated  Accumulated other   Total   of    paid in  surplus/  comprehensive  stockholders’   shares  Amount  capital  (deficit)  losses  equity Balance as of December 31, 202